Magy Abdelwahab scientific , awareness and research activities

17/07/2020

This is a very important topic that I would like to share as it is a cause of significant morbidity , and mortality. If diagnosed EARLY and properly and timely managed can TOTALLY change the QOL of the patient and his whole family. So it's ALL about increased awareness and thinking INHERITED BLEEDING DISORDERS to diagnose them and so properly managed

ISTH Academy; Abdelwahab M. Jul 11 2020; 296325;

06/07/2020

EMICIZUMAB Is it a real change or rather a leap in care of patients with haemophilia affecting dramatically their QOL ...will it stand the challenges of a REAL WORLD EXPERIENCE especially in the pediatric age group.
EMICIZUMAB is a bispecific monoclonal antibody that bridges activated factor IX and factor X to mimic the function of missing activated factor VIII, thereby increasing thrombin formation. So it can be used to treat the most challenging complication, inhibitor formation (30% of patients with severe hemophilia A,).nhibitors significantly increase the cost of care, intensify the financial and psychosocial stressors on patients and their families, and have a negative effect on disease morbidity and mortality by making bleeding episodes more difficult to treat. We conducted this study to answer the question if EMICIZUMAB will stand the challenges of a REAL WORLD EXPERIENCE. The study is entitled,
Assessment of prophylaxis on the outcome of severe hemophilia patients with and without inhibitors.
PRINCIPLE INVESTIGATOR: MAGY ABDELWAHAB
Project highlights This study included the first severe Haemophilia A paediatric patient( MHM) with high titre inhibitors started on EMICIZUMAB in Egypt enrolled and followed up by Dr MAGY ABDELWAHAB . The patient showed significant improvement in bleeding rate and severity, joint status and mobility which was reflected on the patient's and his family's QOL😊😊😊😊
A successful story with many more to come

29/06/2020

Hemophilia/VWD Overview’’ and discussion about challenges in COVID 19 pandemic*

• The speaker is:

*_Prof. Dr. Magy AbdelWahab_* (Professor of Pediatric Hematology at Cairo University)

• Date and time: *Monday, the 29th of June 2020 from 20:00 to 21:00 pm*

• The main outlines of the meeting:
-Haemophilia overview
-VWD disease overview
- Clinical presentation of Haemophilia and VWD
- Diagnosis and treatment
-COVID- 19 in the paediatric age group
- COVID- 19 challenges in Haemophilia


o Summary and conclusion

To access the meeting:
1-kindly download "webex application" from google play or app store
https://play.google.com/store/apps/details?id=com.cisco.webex.meetings

2- click this link https://onetakeda.webex.com/onetakeda/j.php?MTID=m4f9cb839ee348b63fbaca8953af89e87 next Monday at 8:00 PM

3- follow installation steps and then choose "use internet for audio"

Meeting number(access code): 1318010188
Meeting password:
MMuAY526Nf@

You attendance is highly appreciated 😊

13/08/2019

Love the life you live or
Live the life you love

26/05/2019

Thought of the day,
Life is a journey not a destination

12/05/2019

Gaucher disease type 3 in a nutshellGaucher disease type 3(GD3) was initially categorized as chronic neuropathic form of GD with a slowly progressive course. Neuronopathic Gaucher disease (GD 2 and GD3) is less common than GD1, estimated to occur in one in 100,000-300,000 births.1 GD3 approximately represents 5-14% of GD patients with a much higher prevalence in Asia and Egypt. GD 3 patients show wide phenotypic variability ranging from early onset of severe neurological manifestations, reminiscent of GD2, to late-onset neurological manifestations.2 Patients typically have marked visceral and hematological disease and some exhibit bone and lung disease and other rarer complications, such as cardiac.3

None of the currently available therapies, however, have been shown to be effective in treating the neuronopathic disease manifestations. ERT has the potential to lead to favourable outcomes by alleviating the visceral and haematological aspects of the disease and improving quality of life.1
A recent evaluation of a large paediatric GD3 cohort from the International Collaborative Gaucher Group Gaucher Registry provided clear evidence that imiglucerase ERT improved even severe haematologic and visceral manifestations in children and adolescents with GD3 within the first 5 years of treatment, and often after only 12 months.
In this cohort of 253 patients, 37 deaths occured over a median follow up period of 7.5 person-years. A Kaplan Meier analysis indicated the probability of surviving for at least 5 years after starting ERT was 92%, 10 years was 82% and 20 years was 76%. Therefore such potentially severely affected patients may gain benefit from ERT in respect to hematological and organ manifestations, and also growth, which may help them to lead productive lives.3

1. Nalysnyk L et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology, 2016. http://dx.doi.org/10.1080/10245332.2016.1240391
2. Abdelwahab M, Blankenship D, Schiffmann R.Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt.
Neurol Genet. 2016 Feb 25;2(2):e55. doi: 10.1212/NXG.0000000000000055.

3. El-Beshlawy A et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol Gen Metab. 2016. http://dx.doi.org/10.1016/j.ymgme.2016.12.001

(2017). Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology: Vol. 22, No. 2, pp. 65-73.

27/04/2019

Happy to celebrate Rare disease day 2019 awareness with undegraduate students and Kas ElAiny staff members